Ischemia Reperfusion Injury – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Ischemia Reperfusion Injury – Pipeline Review, H1 2017’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury

The report reviews pipeline therapeutics for Ischemia Reperfusion Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ischemia Reperfusion Injury therapeutics and enlists all their major and minor projects

The report assesses Ischemia Reperfusion Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amyndas Pharmaceuticals LLC

Angion Biomedica Corp

Biomedica Management Corp (Inactive)

Bolder Biotechnology Inc

Corline Biomedical AB

Curatis Pharma GmbH

Erimos Pharmaceuticals LLC

Hope Pharmaceuticals Inc

Ischemix Inc

Kowa Company Ltd

NovelMed Therapeutics Inc

Omeros Corp

Opsona Therapeutics Ltd

Orexo AB

Pharming Group NV

Prolong Pharmaceuticals LLC

Proteo Inc

Prothix BV

Recordati SpA

SBI Pharmaceuticals Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Ischemia Reperfusion Injury - Overview 7

Ischemia Reperfusion Injury - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 15

Products under Development by Universities/Institutes 17

Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 20

Amyndas Pharmaceuticals LLC 20

Angion Biomedica Corp 20

Biomedica Management Corp (Inactive) 21

Bolder Biotechnology Inc 21

Corline Biomedical AB 22

Curatis Pharma GmbH 22

Erimos Pharmaceuticals LLC 23

Hope Pharmaceuticals Inc 23

Ischemix Inc 24

Kowa Company Ltd 24

NovelMed Therapeutics Inc 25

Omeros Corp 25

Opsona Therapeutics Ltd 26

Orexo AB 26

Pharming Group NV 27

Prolong Pharmaceuticals LLC 27

Proteo Inc 28

Prothix BV 28

Recordati SpA 29

SBI Pharmaceuticals Co Ltd 29

Ischemia Reperfusion Injury - Therapeutics Assessment 30

Assessment by Target 30

Assessment by Mechanism of Action 33

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Ischemia Reperfusion Injury - Drug Profiles 40

AM/AMBP-1 - Drug Profile 40

aminolevulinic acid hydrochloride - Drug Profile 41

ANV-6L15 - Drug Profile 42

AP-39 - Drug Profile 43

APP-103 - Drug Profile 44

BB-3 - Drug Profile 45

BBT-059 - Drug Profile 49

BMC-011 - Drug Profile 50

C1 esterase inhibitor (recombinant) - Drug Profile 51

CMX-2043 - Drug Profile 58

CRX-526 - Drug Profile 60

Curaglutide - Drug Profile 61

Des-Asp Angiotensin 1 - Drug Profile 62

EP-80317 - Drug Profile 63

FDY-5301 - Drug Profile 64

hemin (human) - Drug Profile 65

KN-93 - Drug Profile 66

MG-53 - Drug Profile 68

mirococept - Drug Profile 70

Monoclonal Antibodies to Inhibit MMP-8 for Renal Ischemia and Shock - Drug Profile 71

Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 72

Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile 74

Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile 75

Neutrolide - Drug Profile 76

NK-104 NP - Drug Profile 78

NP-202 - Drug Profile 79

Oligonucleotide for Oncology and Cardiovascular Diseases - Drug Profile 80

OMS-721 - Drug Profile 81

OPN-305 - Drug Profile 88

PEG-HCC - Drug Profile 91

Peptides to Modulate SRC Family Kinase for Ischemia Reperfusion Injury - Drug Profile 92

PRO-02 - Drug Profile 93

R-190 - Drug Profile 94

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 96

Recombinant Protein for Age Related Macular Degeneration - Drug Profile 97

Recombinant Protein to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile 98

Recombinant Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile 99

Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 100

Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile 101

Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 102

Renaparin - Drug Profile 103

Sanguinate - Drug Profile 104

Small Molecule to Agonize Adenosine Receptor for Neurodegenerative Diseases and Ischemia Reperfusion Injury - Drug Profile 106

Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 107

Small Molecule to Inhibit HSP90 for Ischemia Reperfusion Injury - Drug Profile 108

Small Molecules for Ischemia Reperfusion Injury - Drug Profile 109

Small Molecules for Ischemia Reperfusion Injury - Drug Profile 110

Small Molecules for Ischemia Reperfusion Injury - Drug Profile 111

Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 112

Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile 113

Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug Profile 114

Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 115

Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 116

sodium nitrite - Drug Profile 117

Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 118

Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 119

terameprocol - Drug Profile 120

tiprelestat - Drug Profile 121

TMS-007 - Drug Profile 125

UCF-101 - Drug Profile 126

UWA-TAT - Drug Profile 127

Vanadis-03 - Drug Profile 128

VCP-746 - Drug Profile 129

YQ-23 - Drug Profile 130

Ischemia Reperfusion Injury - Dormant Projects 131

Ischemia Reperfusion Injury - Discontinued Products 134

Ischemia Reperfusion Injury - Product Development Milestones 135

Featured News & Press Releases 135

Appendix 142

Methodology 142

Coverage 142

Secondary Research 142

Primary Research 142

Expert Panel Validation 142

Contact Us 142

Disclaimer 143

List of Tables

List of Tables

Number of Products under Development for Ischemia Reperfusion Injury, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Ischemia Reperfusion Injury – Pipeline by Amyndas Pharmaceuticals LLC, H1 2017

Ischemia Reperfusion Injury – Pipeline by Angion Biomedica Corp, H1 2017

Ischemia Reperfusion Injury – Pipeline by Biomedica Management Corp (Inactive), H1 2017

Ischemia Reperfusion Injury – Pipeline by Bolder Biotechnology Inc, H1 2017

Ischemia Reperfusion Injury – Pipeline by Corline Biomedical AB, H1 2017

Ischemia Reperfusion Injury – Pipeline by Curatis Pharma GmbH, H1 2017

Ischemia Reperfusion Injury – Pipeline by Erimos Pharmaceuticals LLC, H1 2017

Ischemia Reperfusion Injury – Pipeline by Hope Pharmaceuticals Inc, H1 2017

Ischemia Reperfusion Injury – Pipeline by Ischemix Inc, H1 2017

Ischemia Reperfusion Injury – Pipeline by Kowa Company Ltd, H1 2017

Ischemia Reperfusion Injury – Pipeline by NovelMed Therapeutics Inc, H1 2017

Ischemia Reperfusion Injury – Pipeline by Omeros Corp, H1 2017

Ischemia Reperfusion Injury – Pipeline by Opsona Therapeutics Ltd, H1 2017

Ischemia Reperfusion Injury – Pipeline by Orexo AB, H1 2017

Ischemia Reperfusion Injury – Pipeline by Pharming Group NV, H1 2017

Ischemia Reperfusion Injury – Pipeline by Prolong Pharmaceuticals LLC, H1 2017

Ischemia Reperfusion Injury – Pipeline by Proteo Inc, H1 2017

Ischemia Reperfusion Injury – Pipeline by Prothix BV, H1 2017

Ischemia Reperfusion Injury – Pipeline by Recordati SpA, H1 2017

Ischemia Reperfusion Injury – Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Ischemia Reperfusion Injury – Dormant Projects, H1 2017

Ischemia Reperfusion Injury – Dormant Projects, H1 2017 (Contd..1), H1 2017

Ischemia Reperfusion Injury – Dormant Projects, H1 2017 (Contd..2), H1 2017

Ischemia Reperfusion Injury – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Ischemia Reperfusion Injury, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports